官方服务：
资源简介：
In vivo Self-assembled Nano-PROTAC for dual Degradation of AR and HSP90 to Overcome Castration-Resistant Prostate Cancer Resistance
应用场景：
创建时间：
2025-09-19
相关数据集
Expression data from prostate cancer cell lines C4-2B (enzalutamide sensitive) and C4-2B-MDVR (enzalutamide resistant) cells. Homo sapiens
Prostate cancer C4-2B cells were cultured in enzalutamide in a dose-escalation manner. After sixty passages cells were resistant to enzalutamide, with a specific sets of genes been deregulated. We per
NIAID Data Ecosystem50
Discovery of Histone Deacetylase 8‑Specific Proteolysis-Targeting Chimeras with Anticancer Activity against Hematological Malignancies
Histone deacetylase 8 (HDAC8) has emerged as promising therapeutic target for several malignancies. In this study, we developed two series of cereblon (CRBN)-recruiting proteolysis-targeting chimeras
NIAID Data Ecosystem30
Multivalent Peptide-Guided EZH2 Degradation Sensitizes Immune Checkpoint Therapy in TNBC
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Although an immune checkpoint blockade can reduce metastasis, its effectiveness is hindered by the immunosuppressi
NIAID Data Ecosystem20
Discovery of LL-K8-22: A Selective, Durable, and Small-Molecule Degrader of the CDK8-Cyclin C Complex
The CDK8–cyclin C complex is an important anti-tumor target, but unlike CDK8, cyclin C remains undruggable. Modulators regulating cyclin C activity directly are still under development. Here, a series
Figshare2023-03-17 更新30
Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP
Inspired by the success of dual-targeting drugs, especially bispecific antibodies, we propose to combine the concept of proteolysis targeting chimera (PROTAC) and dual targeting to design and synthesi
Figshare2021-05-26 更新30
